Skip to main content

Advertisement

SpringerLink
Log in

Role of FDG-PET/CT in stage 1–4 malignant melanoma patients

  • Original Paper
  • Published:
European Journal of Plastic Surgery Aims and scope Submit manuscript

Abstract

Background

The number of patients diagnosed with malignant melanoma (MM) has increased over several years. Despite early diagnosis of MM and therefore better prognosis, the number of FDG-PET/CT scans (PET/CT) seems to be increasing. This study aimed to describe all MM patients who were PET/CT scanned in 2012 at a department of plastic surgery and to analyze the pattern of referral and outcome of PET/CT scans of these patients all back from early diagnosis of the patient in the period 2008–2012.

Methods

All patients with MM stages 1–4 (AJCC stages) and melanoma of unknown primary (MUP) who were PET/CT scanned in 2012 were included. This resulted in a study group of 58 patients with 109 PET/CT scans during the study period 2008–2012.

Results

Indications for referring stages 1 and 2 patients to PET/CT were usually based on subjective symptoms of disease, whilst patients in stages 3 and 4 were usually appointed to a PET/CT based on objective, radiological or histological signs of relapse. Approximately, two thirds of the PET/CT scans of stages 1 and 2 patients, respectively, were negative, which is twice as many compared to stages 3–4. Five patients were upgraded in stage because of a biopsy taken after PET/CT. The number of additional examinations triggered per PET/CT increased with the stages.

Conclusions

Some PET/CT scans of stages 1 and 2, MM patients might have been unnecessary considering the vague indications for referral and the relatively large number of negative scans. Earlier, there was no national guideline for the use of PET/CT scans of MM patients. Hopefully, the recently published guideline from The Danish Health Board will help optimize the cost-benefit of each PET/CT scan.

Level of Evidence: Level IV, diagnostic study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Erdmann F, Lortet-Tieulent J, Schüz J, et al. (2013) International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? Int J Cancer 132(2):385–400

  2. The Danish Cancer Registry. 2013 report. Available from www.ssi.dk. Accessed 1 Dec 2015.

  3. Cho E, Rosner BA, Feskanich D, Colditz GA (2005) Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 23(12):2669–2675

    Article  PubMed  Google Scholar 

  4. Sundhedsstyrelsen (2012) Pakkeforløb for modermærkekræft. Available from www.sst.dk. Accessed 1 Dec 2015.

  5. Balch CM, Gershenwald JE, Soong SJ, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206

  6. Mohr P, Eggermont AM, Hauschild A, Buzaid A (2009) Staging of cutaneous melanoma. Ann Oncol 20(Suppl 6):vi14–vi21

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ho Shon IA, Chung DK, Saw RP, Thompson JF (2008) Imaging in cutaneous melanoma. Nucl Med Commun 29(10):847–876

    Article  PubMed  Google Scholar 

  8. Gao G, Gong B, Shen W (2013) Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: comparison with 18FDG PET alone and CT alone. Surg Oncol 22(3):195–200

    Article  PubMed  Google Scholar 

  9. Bourgeois AC, Chang TT, Fish LM, Bradley YC (2013) Positron emission tomography/computed tomography in melanoma. Radiol Clin N Am 51(5):865–879

    Article  PubMed  Google Scholar 

  10. Danielsen M, Højgaard L, Kjær A, Fischer BM (2013) Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging 4(1):17–28

    PubMed  PubMed Central  Google Scholar 

  11. Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Vander Borght T (2008) Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 249(3):836–844

    Article  PubMed  Google Scholar 

  12. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G (2012) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii86–vii91

    Article  PubMed  Google Scholar 

  13. Francken AB, Bastiaannet E, Hoekstra HJ (2005) Follow-up in patients with localized primary cutaneous melanoma. Lancet Oncol 6:608–621

    Article  PubMed  Google Scholar 

  14. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF (2007) Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 14:1924–1933

    Article  PubMed  Google Scholar 

  15. Francken AB, Accortt NA, Shaw HM, et al. (2008) Follow-up schedules after treatment for malignant melanoma. Br J Surg 95:1401–1407

    Article  CAS  PubMed  Google Scholar 

  16. Garbe C, Paul A, Kohler-Spath H, et al. (2003) Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 21:520–529

    Article  PubMed  Google Scholar 

  17. Meyers MO, Yeh JJ, Frank J, et al. (2009) Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of utility of follow-up staging. Ann Surg Oncol 16:941–947

    Article  PubMed  Google Scholar 

  18. Fields RC, Coit DG (2011) Evidence-based follow-up for the patient with melanoma. Surg Oncol Clin N Am 20:181–200

    Article  PubMed  Google Scholar 

  19. NCCN Clinical practice guidelines in oncology. Melanoma v.2. 2014.

  20. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:3042–3047

    Article  PubMed  PubMed Central  Google Scholar 

  21. Xing Y, Cromwell KD, Cormier JN (2012) Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol Res Pract 2012:941921

    PubMed  Google Scholar 

  22. Leiter U, Meier F, Schittek B, Garbe C (2004) The natural course of cutaneous melanoma. J Surg Oncol 86:172–178

    Article  PubMed  Google Scholar 

  23. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, et al. (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147:62–70

    Article  CAS  PubMed  Google Scholar 

  24. Time course and pattern of metastasis of cutaneous melanoma differ between men and women Liljana Mervic Published: March 6, 2012 doi: 10.1371/journal.pone.0032955

  25. Xing Y, Bronstein Y, Ross MI, et al. (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103(2):129–142

    Article  PubMed  PubMed Central  Google Scholar 

  26. Pflugfelder A, Kochs C, Blum A, et al. (2013) Malignant melanoma S3-guidline “diagnosis, therapy and follow-up of melanoma”. J Dtsch Dermatol Ges 11(Suppl 6):1–126

    PubMed  Google Scholar 

  27. Peric B, Zagar I, Novakovic S, Zgajnar J, Hocevar M (2011) Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma. BMC Cancer 11:328

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ortiz B, Vázquez C, Martínez C, et al. (2003) S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET. Rev Esp Med Nucl 22(2):87–96

    Article  CAS  PubMed  Google Scholar 

  29. Jury CS, McAllister EJ, MacKie RM (2000) Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 143(2):269–274

    Article  CAS  PubMed  Google Scholar 

  30. Reinhardt MJ, Kensy J, Frohmann JP, et al. (2002) Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin 41(3):143–147

    CAS  PubMed  Google Scholar 

  31. Petersen H et al (2015) FDG PET/CT in cancer: comparison of actual use with literature-based recommendations. Eur J Nucl Med Mol Imaging. 2015 Oct 30.

  32. UK Cancer Statistics. Available from http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/skin-cancer/incidence#ref-11. Accessed 1 Apr 2016.

  33. National Cancer Intelligence Network. . Available from http://www.ncin.org.uk/publications/survival_by_stage Accessed 1 Apr 2016.

  34. Sundhedsstyrelsen (2015) Opfølgningsprogram for Modermærkekræft (Melanom). Available from www.sst.dk. Accessed 1 Dec 2015.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Aarhus University Hospital, P.P. Ørumsgade 11, 8000, Aarhus C, Denmark

    Mai Eldon

  2. Department of Plastic Surgery, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark

    Ulrik Knap Kjerkegaard & Lars Bjørn Stolle

  3. Department of Plastic Surgery, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus C, Denmark

    Mette Heisz Ørndrup & Pia Sjøgren

Authors
  1. Mai Eldon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrik Knap Kjerkegaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mette Heisz Ørndrup
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pia Sjøgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lars Bjørn Stolle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mai Eldon.

Ethics declarations

Conflict of interest

Mai Eldon, Ulrik Knap Kjerkegaard, Mette Heisz Ørndrup, Pia Sjøgren2, and Lars Bjørn Stolle declare that they have no conflict of interest.

Ethical standards

For this type of study formal consent is not required.

Patient consent

For this type of study informed consent is not required.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eldon, M., Kjerkegaard, U.K., Ørndrup, M.H. et al. Role of FDG-PET/CT in stage 1–4 malignant melanoma patients. Eur J Plast Surg 40, 47–52 (2017). https://doi.org/10.1007/s00238-016-1228-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00238-016-1228-0

Keywords

Search

Navigation